Anidulafungin in the treatment of invasive fungal infections

Therapeutics and Clinical Risk Management

Volumn 4, Issue 1, 2008, Pages 71-78

  Sabol, Kathryn ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anidulafungin; Candidiasis; Efficacy; Pharmacokinetics pharmacodynamics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; HMR 3270; MICAFUNGIN; PHENYTOIN; RIFAMPICIN; UNCLASSIFIED DRUG; VORICONAZOLE;

ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CANDIDA; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEVER; FLUSHING; HUMAN; HYPOTENSION; INVASIVE CANDIDIASIS; LEUKOPENIA; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

EID: 41549145288     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Alexander BD, Schell WA, Miller JL, et al. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation, 80:868-71.
2. Andes D, Marchillo K, Lowther J, et al. 2003. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother, 47:1187-92.
3. Arathoon EG, Gotuzzo E, Noriega LM, et al. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases, Antimicrob Agents Chemother, 46:451-7.
4. Buell D, Kovanda L, Drake T, et al. 2005. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract M-719.
5. Clancy CJ, Barchiesi F, Falconi DiFrancesco L, et al. 2000. Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management. Eur J Clin Microbiol Infect Dis, 19:585-92.
6. de Wet N, Llanos-Cuentas A, Suleiman J, et al. 2004. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis, 39:842-9.
7. Dowell J, Stogniew M, Krause D. 2003. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. 13th European Congress of Clinical Microbiology and Infectious Diseases.
8. Dowell JA, Knebel W, Ludden T, et al. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol, 44:590-8.
9. Dowell JA, Schranz J, Baruch A, et al. 2005. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol, 45:1373-82.
10. Dowell JA, Stogniew M, Krause D, et al. 2003. Anidulafungin (ANID) pharmacokinetic (PK)/Pharmacodynamic (PD) correlation: Treatment of esophageal candidiasis. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy, Abstract A-1578.
11. Espinel-Ingroff A. 1998. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol, 36:2950-6.
12. Espinel-Ingroff A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol, 20:121-36.
13. Groll AH, Mickiene D, Petraitiene R, et al. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother, 45:2845-55.
14. Gumbo T, Ikeda F, Louie A. 2007a. Glucan synthase inhibitors. In: Nightingale CH, Murakawa T, Ambrose PG, Drusano GL, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. 2nd ed. New York: Informa. Healthcare. p. 355-77.
15. Gumbo T, Chemaly RF, Isada CM, et al. 2002. Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon. Scand J Infect Dis, 34:817-8.
16. Gumbo T, Drusano GL, Liu W, et al. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother, 50:3695-700.
17. Gumbo T, Isada. CM, Hall G, et al. 1999. Candida glabrata Fungemia. Clinical features of 139 patients. Medicine (Baltimore), 78:220-7.
18. Gumbo T, Drusano GL, Liu W, et al. 2007b. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother, 51:968-74.
19. Krause DS, Reinhardt J, Vazquez JA, et al. 2004a. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother, 48:2021-4.
20. Krause DS, Simjee AE, van Rensburg C, et al. 2004b. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis, 39:770-75.
21. Kurtz MB, Abruzzo G, Flattery A, et al. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun, 64:3244-51.
22. Kuse ER, Chetchotisakd P, da Cunha CA, et al. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, 369:1519-27.
23. Louie A, Deziel M, Liu W, et al. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother, 49:5058-68.
24. Mora-Duarte J, Betts R, Rotstein C, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med, 347:2020-9.
25. Nasser RM, Melgar GR, Longworth DL, et al. 1997. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med, 103:25-32.
26. Nguyen MH, Peacock JE Jr, Morris AJ, et al. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med, 100:617-23.
27. Oakley KL, Moore CB, Denning DW 1998. In vitro activity of the echinocandin antifungal agent LY303, 366 in Comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother, 42:2726-30.
28. Pappas PG, Rotstein CM, Betts RF, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis, 45:883-93.
29. Pfizer Inc. 2006. Final package insert for ERAXIS (anidulafungin) for injection. New York.
30. Phillips P, Shafran S, Garber G, et al. 1997. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis, 16:337-45.
31. Reboli AC, Rotstein C, Pappas PG, et al. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med, 356:2472-82.
32. Rex JH, Bennett JE, Sugar AM, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med, 331:1325-30.
33. Rex JH, Pappas PG, Karchmer AW, et al. 2003. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis, 36:1221-8.
34. Serrano MC, Valverde-Conde A, Chavez MM, et al. 2003. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis, 45:131-5.
35. Sobel JD, Bradshaw SK, Lipka CJ, et al. 2007. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis, 44:e46-e49.
36. Sobel JD, Revankar SG. 2007. Echinocandins - first-choice or first-line therapy for invasive candidiasis? N Engl J Med, 356:2525-6.
37. Trissel LA, Ogundele AB. 2005. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health Syst Pharm, 62:834-7.
38. Wiederhold NP, Kontoyiannis DP, Chi J, et al. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis, 190:1464-71.